Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Infectious disease

HCV

HCV E2

In vitro studies solved the structure of the HCV E2 protein, which could aid HCV vaccine and drug design. X-ray crystal and electron microscopy structures of glycosylated fragments of the E2 ectodomain in complex with a Fab fragment of a broadly neutralizing antibody showed a relatively hydrophobic, N-linked glycan-free interaction surface. Structural and mutational analysis showed that the same region of E2 binds CD81, the entry receptor for HCV on liver cells. Next steps include designing small molecule inhibitors targeting the site and testing them for inhibition of viral entry.

SciBX 7(2); doi:10.1038/scibx.2014.57
Published online Jan. 16, 2014

Patent and licensing status undisclosed

Kong, L. et al. Science; published online Nov. 29, 2013;
doi:10.1126/science.1243876
Contact: Mansun Law, The Scripps Research Institute, La Jolla, Calif.
e-mail:
mlaw@scripps.edu

Contact: Andrew B. Ward, same affiliation as above
e-mail:
abward@scripps.edu

Contact: Ian A. Wilson, same affiliation as above
e-mail:
wilson@scripps.edu